Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RNXT
Upturn stock ratingUpturn stock rating

RenovoRx Inc (RNXT)

Upturn stock ratingUpturn stock rating
$1.32
Last Close (24-hour delay)
Profit since last BUY24.53%
upturn advisory
Consider higher Upturn Star rating
BUY since 35 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: RNXT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.5

1 Year Target Price $5.5

Analysts Price Target For last 52 week
$5.5Target price
Low$0.75
Current$1.32
high$1.69

Analysis of Past Performance

Type Stock
Historic Profit -37.32%
Avg. Invested days 35
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 46.81M USD
Price to earnings Ratio -
1Y Target Price 5.5
Price to earnings Ratio -
1Y Target Price 5.5
Volume (30-day avg) 4
Beta 1.32
52 Weeks Range 0.75 - 1.69
Updated Date 06/30/2025
52 Weeks Range 0.75 - 1.69
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.41

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1578.68%

Management Effectiveness

Return on Assets (TTM) -69.73%
Return on Equity (TTM) -136.13%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 33244901
Price to Sales(TTM) 195.05
Enterprise Value 33244901
Price to Sales(TTM) 195.05
Enterprise Value to Revenue 138.52
Enterprise Value to EBITDA -4.72
Shares Outstanding 36572200
Shares Floating 29603759
Shares Outstanding 36572200
Shares Floating 29603759
Percent Insiders 4.42
Percent Institutions 27.55

Analyst Ratings

Rating 2
Target Price 5.5
Buy 2
Strong Buy 2
Buy 2
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

RenovoRx Inc

stock logo

Company Overview

overview logo History and Background

RenovoRx, Inc. is a biopharmaceutical company focused on developing and commercializing innovative targeted therapies for the local treatment of solid tumors. Founded in 2009, it has focused on developing its proprietary RenovoCath delivery system for targeted intra-arterial delivery of therapeutics.

business area logo Core Business Areas

  • Trans-Arterial Micro-Perfusion (TAMP) Therapy: RenovoRx's core business revolves around its TAMP therapy platform, which combines the RenovoCath delivery system with chemotherapeutics to target solid tumors directly. This technology is designed to improve drug delivery to the tumor while minimizing systemic toxicity.

leadership logo Leadership and Structure

Shaun Bagai is the CEO. The company has a board of directors and a management team focused on clinical development, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • RenovoCath Delivery System: The RenovoCath is a proprietary micro-perfusion system used to deliver therapeutic agents directly to tumors via intra-arterial delivery. It is designed to enhance drug penetration and minimize systemic side effects. Market share data is not publicly available as it is still in development and clinical trial stages. Competitors: Boston Scientific, Medtronic in drug delivery technologies, but not specifically TAMP.

Market Dynamics

industry overview logo Industry Overview

The oncology market is large and growing, with increasing demand for targeted therapies that can improve patient outcomes while reducing side effects. Local drug delivery is an evolving field within oncology.

Positioning

RenovoRx is positioned as an innovator in the local drug delivery space, focusing on improving the effectiveness of chemotherapy by targeting tumors directly. Competitive advantages include its proprietary RenovoCath technology and its focus on TAMP therapy.

Total Addressable Market (TAM)

The TAM for local drug delivery in oncology is estimated to be billions of dollars, encompassing various solid tumor types. RenovoRx is positioned to capture a portion of this market with its RenovoCath technology, depending on clinical trial success and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Proprietary RenovoCath technology
  • Focus on targeted drug delivery
  • Potential for improved efficacy and reduced toxicity
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial success
  • Lack of commercialized products
  • Small market capitalization

Opportunities

  • Expansion into new tumor types
  • Partnerships with pharmaceutical companies
  • Positive clinical trial results
  • Increased adoption of local drug delivery

Threats

  • Competition from established drug delivery companies
  • Regulatory hurdles
  • Clinical trial failures
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • BSX
  • MDT
  • Varian Medical Systems (VAR)
  • Elekta (EKTAY)

Competitive Landscape

RenovoRx has a unique approach with TAMP and RenovoCath, but faces competition from established players in drug delivery and oncology. Success depends on demonstrating superior efficacy and safety.

Growth Trajectory and Initiatives

Historical Growth: As a clinical-stage company, historical growth is measured by progress in clinical trials and securing funding.

Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approval of RenovoCath for specific indications, and commercialization efforts. Analyst estimates should be reviewed for specific revenue projections.

Recent Initiatives: Recent initiatives include advancing clinical trials for pancreatic cancer and bile duct cancer, and securing additional funding to support these efforts.

Summary

RenovoRx is a clinical-stage biopharmaceutical company with a proprietary drug delivery system focused on targeted cancer therapies. Its success hinges on the outcomes of its clinical trials and its ability to secure regulatory approvals. The company faces challenges typical of early-stage biotechs, including limited resources and reliance on positive clinical data. While innovative, it will require careful management to navigate the competitive landscape.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • RenovoRx SEC Filings (10-K, 10-Q)
  • Company Website
  • Analyst Reports (where available)
  • Industry Reports on Oncology and Drug Delivery

Disclaimers:

This analysis is based on publicly available information and should not be considered investment advice. The biotechnology industry is inherently risky, and investors should conduct thorough due diligence before making any investment decisions. Market share data are estimates based on available information and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About RenovoRx Inc

Exchange NASDAQ
Headquaters Mountain View, CA, United States
IPO Launch date 2021-08-26
CEO, Secretary & Director Mr. Shaun R. Bagai
Sector Healthcare
Industry Biotechnology
Full time employees 10
Full time employees 10

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.